Nanotechnology in the

Treatment of HIV

Adrian Vigil
What is HIV?

 Human Immunodeficiency Virus

 Acquired Immunodeficiency Syndrome

 Mode of Transmission
Current Treatment

HAART Issues With Current

 Aims to suppress HIV
Treatments
 Prevention of HIV turning
into AIDS  Adverse affects

 Dosing

 Bioavailability
Goals for Nanomedicine-Based Treatment

 Intracellular Concentration of Drugs

 Strengthen Antiretroviral Activity

 Bioavailability

 Reduce Toxicity

 Reduce Frequency of Dosing

Intravaginal Microbicide

 Formed From Anionic Polymers and Polysaccharides

 Sterilizing Immunity

 Application

 Aim to Resist Viral Challenge

 Types
 Target Virus
 Inhibit Viral Bonding
Suppression
 Mirror Current Treatments

 Goals

 Drug Intake

 Controlled Release Delivery

 Nanosuspensions

 Liposomes
 120nm to 200nm
 Mannose and Galactose
Suppression Delivery Systems
Gene Therapy

 Goals

 RNA

 Nanotubes

 Efficiency

 CRISPR
Immunotherapy

 Goals

 DermaVir Patch
 Phase 2 Clinical Trials
 Targeted Nanoparticle System
Vaccine Delivery

 Targeted Specific Cells

 Efficacy
Works Cited
 Kumar, Lalit, et al. “Nanotechnology: A Magic Bullet for HIV AIDS Treatment.”
Artificial Cells, Nanomedicine & Biotechnology, vol. 43, no. 2, Apr. 2015, pp.
71–86. EBSCOhost, doi:10.3109/21691401.2014.883400.

 Parboosing, Raveen, et al. “Nanotechnology and the Treatment of HIV

Infection.” Viruses (1999-4915), vol. 4, no. 4, Apr. 2012, pp. 488–520.
EBSCOhost, doi:10.3390/v4040488.

 Boyapalle, Sandhya, et al. “Nanotechnology Applications to HIV Vaccines and

Microbicides.” Journal of Global Infectious Diseases, vol. 4, no. 1, Jan. 2012,
pp. 62–68. EBSCOhost, doi:10.4103/0974-777X.93764.